Safety and Tolerability of Metformin and Naproxen for Cancer Prevention in Fanconi Anemia

Finding effective ways to slow down or prevent the development of cancer in people with Fanconi anemia (FA) is a critical medical priority. Individuals with FA are at dramatically higher risk of developing aggressive cancers, particularly of the head and neck, and these cancers are difficult to treat with standard therapies such as surgery, chemotherapy or radiation. Because options for treatment are limited and outcomes are often poor, prevention strategies are urgently needed. In this study, the investigators will test two widely available drugs, metformin and naproxen, to evaluate whether

Trial Details

NCT ID

NCT07901959

Phase

PHASE1

Sponsor

Rockefeller University

Status

RECRUITING

Cancer Type

Head and Neck Cancer

Interventions

Metformin
Naproxen Sodium

Locations (sample)

Minneapolis, Minnesota, United States|44.97997,-93.26384
New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

Confirmed Diagnosis:
Fanconi anemia confirmed by review of past molecular testing (including chromosomal breakage testing results) Age
Age ≥18 years. Functional Status
Karnofsky performance scale ≥70%.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →